Terms: = Ovarian cancer AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Prognosis
22 results:
1. Compartment-specific multiomic profiling identifies src and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract] [Full Text] [Related]
2. ALKBH5 activates FAK signaling through m6A demethylation in
Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
[No Abstract] [Full Text] [Related]
3. src-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway.
Wang Y; Luo X; Wu N; Liao Q; Wang J
Med Oncol; 2023 Jan; 40(2):76. PubMed ID: 36625999
[TBL] [Abstract] [Full Text] [Related]
4. Polarity switching of ovarian cancer cell clusters via src family kinase is involved in the peritoneal dissemination.
Kawata M; Kondo J; Onuma K; Ito Y; Yokoi T; Hamanishi J; Mandai M; Kimura T; Inoue M
Cancer Sci; 2022 Oct; 113(10):3437-3448. PubMed ID: 35848881
[TBL] [Abstract] [Full Text] [Related]
5. Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
Erdogan MA; Ashour A; Yuca E; Gorgulu K; Ozpolat B
Cell Signal; 2021 May; 81():109938. PubMed ID: 33539938
[TBL] [Abstract] [Full Text] [Related]
6. MUC Glycoproteins: Potential Biomarkers and Molecular Targets for cancer Therapy.
Ratan C; Cicily K D D; Nair B; Nath LR
Curr Cancer Drug Targets; 2021; 21(2):132-152. PubMed ID: 33200711
[TBL] [Abstract] [Full Text] [Related]
7. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.
Gong G; Lin T; Yuan Y
J Ovarian Res; 2020 Mar; 13(1):30. PubMed ID: 32192517
[TBL] [Abstract] [Full Text] [Related]
8. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
Rada M; Nallanthighal S; Cha J; Ryan K; Sage J; Eldred C; Ullo M; Orsulic S; Cheon DJ
Oncogene; 2018 Aug; 37(35):4809-4820. PubMed ID: 29769618
[TBL] [Abstract] [Full Text] [Related]
9. Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and src inhibits epithelial-mesenchymal transition in cancer.
Barneh F; Mirzaie M; Nickchi P; Tan TZ; Thiery JP; Piran M; Salimi M; Goshadrou F; Aref AR; Jafari M
Brief Bioinform; 2019 Mar; 20(2):717-731. PubMed ID: 29726962
[TBL] [Abstract] [Full Text] [Related]
10. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
[TBL] [Abstract] [Full Text] [Related]
11. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract] [Full Text] [Related]
12. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Park GB; Chung YH; Kim D
Oncol Rep; 2017 May; 37(5):3137-3145. PubMed ID: 28350104
[TBL] [Abstract] [Full Text] [Related]
13. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract] [Full Text] [Related]
14. TRPM7 is required for ovarian cancer cell growth, migration and invasion.
Wang J; Liao QJ; Zhang Y; Zhou H; Luo CH; Tang J; Wang Y; Tang Y; Zhao M; Zhao XH; Zhang QY; Xiao L
Biochem Biophys Res Commun; 2014 Nov; 454(4):547-53. PubMed ID: 25450691
[TBL] [Abstract] [Full Text] [Related]
15. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer.
Zhang W; Liu Y; Sun N; Wang D; Boyd-Kirkup J; Dou X; Han JD
Cell Rep; 2013 Aug; 4(3):542-53. PubMed ID: 23933257
[TBL] [Abstract] [Full Text] [Related]
16. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation.
Kiefel H; Bondong S; Pfeifer M; Schirmer U; Erbe-Hoffmann N; Schäfer H; Sebens S; Altevogt P
Carcinogenesis; 2012 Oct; 33(10):1919-29. PubMed ID: 22764136
[TBL] [Abstract] [Full Text] [Related]
17. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.
Dozynkiewicz MA; Jamieson NB; Macpherson I; Grindlay J; van den Berghe PV; von Thun A; Morton JP; Gourley C; Timpson P; Nixon C; McKay CJ; Carter R; Strachan D; Anderson K; Sansom OJ; Caswell PT; Norman JC
Dev Cell; 2012 Jan; 22(1):131-45. PubMed ID: 22197222
[TBL] [Abstract] [Full Text] [Related]
18. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH
Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455
[TBL] [Abstract] [Full Text] [Related]
19. Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells.
Lis R; Capdet J; Mirshahi P; Lacroix-Triki M; Dagonnet F; Klein C; Mirshahi M; Fournié JJ; Rafii A; Poupot M
Int J Oncol; 2010 Dec; 37(6):1453-61. PubMed ID: 21042713
[TBL] [Abstract] [Full Text] [Related]
20. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
Siu MK; Chan HY; Kong DS; Wong ES; Wong OG; Ngan HY; Tam KF; Zhang H; Li Z; Chan QK; Tsao SW; Strömblad S; Cheung AN
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18622-7. PubMed ID: 20926745
[TBL] [Abstract] [Full Text] [Related]
[Next]
